As non-specific PS accumulation and the associated phototoxicity still remains a major challenge in PDT, exploitation of tumor surface markers, including growth factor receptors (VEGFR, EGFR) [293–296], transferrin receptors (TfR) [297], folate receptors (FR) [298], low-density lipo protein (LDL) receptors [299], glucose transporters [300] and integrin receptors [301] for active targeting offers a viable option to minimize these side-effects. The gene discussed is TFRC; the disease is neoplasm.